- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 6, Pages 1292
Publisher
MDPI AG
Online
2021-03-15
DOI
10.3390/cancers13061292
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy
- (2021) Claire M. Patterson et al. Communications Biology
- Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
- (2020) Courtney D. DiNardo et al. BLOOD
- Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax
- (2020) Piers Blombery et al. BLOOD
- Targeting MCL-1 in hematologic malignancies: Rationale and progress
- (2020) AndrewH. Wei et al. BLOOD REVIEWS
- AMG-176, an Mcl-1 antagonist, shows preclinical efficacy in chronic lymphocytic leukemia
- (2020) Xue Yi et al. CLINICAL CANCER RESEARCH
- Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies.
- (2020) Curtis Andrew Lachowiez et al. JOURNAL OF CLINICAL ONCOLOGY
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
- (2020) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- AZD4320, a dual inhibitor of Bcl-2 and Bcl-xL, induces tumor regression in hematological cancer models without dose-limiting thrombocytopenia
- (2020) Srividya B Balachander et al. CLINICAL CANCER RESEARCH
- Phase IB study of osimertinib in combination with navitoclax in EGFR-mutant NSCLC following resistance to initial EGFR therapy (ETCTN 9903)
- (2020) Erin M. Bertino et al. CLINICAL CANCER RESEARCH
- Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
- (2020) Shaji K Kumar et al. LANCET ONCOLOGY
- Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
- (2019) Rumani Singh et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
- (2019) Andrew H. Wei et al. JOURNAL OF CLINICAL ONCOLOGY
- Obatoclax, a BH3 Mimetic, Enhances Cisplatin-Induced Apoptosis and Decreases the Clonogenicity of Muscle Invasive Bladder Cancer Cells via Mechanisms That Involve the Inhibition of Pro-Survival Molecules as Well as Cell Cycle Regulators
- (2019) Thomas Steele et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia
- (2019) Eugen Tausch et al. HAEMATOLOGICA
- Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
- (2019) Kirsten Fischer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia
- (2019) Kent T. J. Chen et al. PHARMACEUTICAL RESEARCH
- Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations
- (2019) Richard W. Birkinshaw et al. Nature Communications
- Treatment of Relapsed/Refractory Non Hodgkin Lymphoma Patients with Venetoclax Therapy: A Single-Center Evaluation of off-label use
- (2019) Mitchell E. Hughes et al. Clinical Lymphoma Myeloma & Leukemia
- How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia
- (2019) Brian A. Jonas et al. LEUKEMIA
- Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells
- (2018) Mohamed Rahmani et al. CANCER RESEARCH
- Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial
- (2018) Stephan Stilgenbauer et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
- (2018) Courtney D DiNardo et al. LANCET ONCOLOGY
- Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
- (2018) John F. Seymour et al. NEW ENGLAND JOURNAL OF MEDICINE
- S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth
- (2018) Patrick Casara et al. Oncotarget
- Targeting BCL-2 regulated apoptosis in cancer
- (2018) Kirsteen J. Campbell et al. Open Biology
- Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
- (2018) Courtney D. DiNardo et al. BLOOD
- Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia
- (2018) Piers Blombery et al. Cancer Discovery
- Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- (2017) Matthew S. Davids et al. JOURNAL OF CLINICAL ONCOLOGY
- Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
- (2017) John F Seymour et al. LANCET ONCOLOGY
- Release of Cytochrome C from Bax Pores at the Mitochondrial Membrane
- (2017) Mingzhen Zhang et al. Scientific Reports
- Disordered clusters of Bak dimers rupture mitochondria during apoptosis
- (2017) Rachel T Uren et al. eLife
- The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism
- (2016) M. A. Anderson et al. BLOOD
- Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells
- (2016) X. Niu et al. CLINICAL CANCER RESEARCH
- Venetoclax: First Global Approval
- (2016) Emma D. Deeks DRUGS
- Inactivation of prosurvival Bcl-2 proteins activates Bax/Bak through the outer mitochondrial membrane
- (2016) Katelyn L. O'Neill et al. GENES & DEVELOPMENT
- Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
- (2016) Stephan Stilgenbauer et al. LANCET ONCOLOGY
- Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
- (2016) E. A. Punnoose et al. MOLECULAR CANCER THERAPEUTICS
- Mitochondria—Judges and Executioners of Cell Death Sentences
- (2016) Patrick D. Bhola et al. MOLECULAR CELL
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bax/Bak activation in the absence of Bid, Bim, Puma and p53
- (2016) J Zhang et al. Cell Death & Disease
- BCL2 Inhibition by Venetoclax: Targeting the Achilles' Heel of the Acute Myeloid Leukemia Stem Cell?
- (2016) V. A. Pullarkat et al. Cancer Discovery
- Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
- (2016) M. Konopleva et al. Cancer Discovery
- Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells
- (2016) Juraj Bodo et al. Oncotarget
- Somatic TP53 Mutations in the Era of Genome Sequencing
- (2016) Pierre Hainaut et al. Cold Spring Harbor Perspectives in Medicine
- Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+lymphoid malignancies
- (2015) Andrew W. Roberts et al. BRITISH JOURNAL OF HAEMATOLOGY
- Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors
- (2015) Anthony W. Tolcher et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma
- (2015) M. Klanova et al. CLINICAL CANCER RESEARCH
- Structure-Based Lead Optimization and Biological Evaluation of BAX Direct Activators as Novel Potential Anticancer Agents
- (2015) Mariano Stornaiuolo et al. JOURNAL OF MEDICINAL CHEMISTRY
- Direct Activation of Bax Protein for Cancer Therapy
- (2015) Zhiqing Liu et al. MEDICINAL RESEARCH REVIEWS
- Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
- (2015) Steven M Chan et al. NATURE MEDICINE
- Bcl-2 family proteins as regulators of cancer cell invasion and metastasis: a review focusing on mitochondrial respiration and reactive oxygen species
- (2015) Hong-Duck Um Oncotarget
- MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199
- (2015) Juliana M. Benito et al. Cell Reports
- BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma
- (2014) C. Correia et al. BLOOD
- Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma
- (2014) V. Fresquet et al. BLOOD
- A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors
- (2014) James M. Cleary et al. INVESTIGATIONAL NEW DRUGS
- A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors
- (2014) Gordana Vlahovic et al. INVESTIGATIONAL NEW DRUGS
- Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199
- (2014) X Niu et al. LEUKEMIA
- A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia
- (2014) Aaron D. Schimmer et al. PLoS One
- Apoptotic pore formation is associated with in-plane insertion of Bak or Bax central helices into the mitochondrial outer membrane
- (2014) Dana Westphal et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Defective DROSHA processing contributes to downregulation of MiR-15/-16 in chronic lymphocytic leukemia
- (2013) D Allegra et al. LEUKEMIA
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Therapeutic potential of gossypol: An overview
- (2013) Hoda Keshmiri-Neghab et al. PHARMACEUTICAL BIOLOGY
- Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
- (2013) R. Pan et al. Cancer Discovery
- Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process
- (2012) M. Rahmani et al. BLOOD
- Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
- (2012) C. M. Rudin et al. CLINICAL CANCER RESEARCH
- Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia
- (2011) D. Sampath et al. BLOOD
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis
- (2011) Melisa A. Martínez-Paniagua et al. CELL CYCLE
- Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
- (2011) Leena Gandhi et al. JOURNAL OF CLINICAL ONCOLOGY
- The human stem cell hierarchy is defined by a functional dependence on Mcl-1 for self-renewal capacity
- (2010) C. J. V. Campbell et al. BLOOD
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
- (2010) Wyndham H Wilson et al. LANCET ONCOLOGY
- Different forms of cell death induced by putative BCL2 inhibitors
- (2009) M Vogler et al. CELL DEATH AND DIFFERENTIATION
- An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer
- (2009) G. Liu et al. CLINICAL CANCER RESEARCH
- Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia
- (2009) Edurne San José-Eneriz et al. EUROPEAN JOURNAL OF CANCER
- Gossypol suppresses NF-κB activity and NF-κB-related gene expression in human leukemia U937 cells
- (2008) Dong-Oh Moon et al. CANCER LETTERS
- A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies
- (2008) A. D. Schimmer et al. CLINICAL CANCER RESEARCH
- Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 Proteins
- (2008) Cheol-Min Park et al. JOURNAL OF MEDICINAL CHEMISTRY
- Selection against PUMA Gene Expression in Myc-Driven B-Cell Lymphomagenesis
- (2008) S. P. Garrison et al. MOLECULAR AND CELLULAR BIOLOGY
- Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa
- (2008) Y. Meng et al. MOLECULAR CANCER THERAPEUTICS
- Structure of transmembrane pore induced by Bax-derived peptide: Evidence for lipidic pores
- (2008) S. Qian et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started